Rational approach to implementation of prostate cancer antigen 3 into clinical care. - Wikidata - awgldk - TriplyDB

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

http://www.wikidata.org/entity/Q39888907

about

Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care.In-depth proteomic analyses of direct expressed prostatic secretions.Novel diagnostic biomarkers for prostate cancer.Can urinary PCA3 supplement PSA in the early detection of prostate cancer?Regulators of gene expression as biomarkers for prostate cancer Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis.Long noncoding RNAs in prostate cancer: mechanisms and applications Beyond PSA: the next generation of prostate cancer biomarkers.Biomarkers for the diagnosis of new and recurrent prostate cancer.The genomic landscape of prostate cancer Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer.Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.Progensa™ PCA3 test for prostate cancer.Age-specific PCA3 score reference values for diagnosis of prostate cancer.Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score.Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.Does intravenous cefuroxime improve the efficacy of ciprofloxacin for preventing infectious complications after transrectal prostate biopsy? A prospective comparative study.Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer.Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.Maximizing outcomes in genitourinary cancers across the treatment continuum.Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer.

P2860

Q33581483-672260DD-6C56-4E5F-B3AB-2737053FBF88 Q33849273-4846E501-23F8-43E2-9876-229361EED1BA Q34231678-FABE5966-6C54-49BF-BB4F-A9D19F28BFBB Q34692263-C4050316-F05B-4AEF-B3B6-F79CCD8DB14B Q36439912-715294FD-70D8-4567-A6E3-09241C2E8AC5 Q36886346-0C9E07B3-72BA-41A8-B729-AB6B4B3E63EE Q36997564-3A757D31-A684-49CF-B2DC-3B56DA7B13A2 Q37238101-3A5D6E07-1C3F-493A-92B2-1987974C9C8F Q38052926-80871237-3F73-45D1-9099-4E4AA675E486 Q38109474-8E20FA1D-057F-470B-A28B-D967E5FCBE51 Q38144712-05A940F5-8BEC-4DC7-8917-FC8634A2EA3D Q38215157-54F110F4-5E5C-4E88-B5FF-46CDB345394D Q38568275-B6859C6B-D561-40CF-9F81-B64A2230C4C6 Q39771683-0304A2ED-C920-4490-9339-30707ECBC9F4 Q39996595-CD9DCE21-3067-4F4F-9596-6A56F6A7A2D6 Q40072464-AEF82098-8537-431F-B44C-3A262318BB82 Q40167317-E980695E-E75C-4EB4-B196-31E3EEBD4C35 Q40266354-36681690-5300-41F5-B0EB-B752A05DAAC3 Q40985522-EC7D765E-E211-43DA-B8A4-653C67F2CBBA Q42151262-0787F317-CE0C-43E1-A080-C32E561DC08C Q43169980-056E9D6A-2DE5-4C61-9582-FA2F0E978D5E Q50246373-2D002D51-93D8-47D2-B3F5-3F977E35D65B Q52569296-053E8E23-77A3-4C2C-8965-1750E73836EB

P2860

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

http://www.wikidata.org/entity/Q39888907

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

@en

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

@nl

type

label

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

@en

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

@nl

prefLabel

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

@en

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

@nl

P1433

Q39888907-B265C659-4B23-45D5-A76D-9E20CECFD5AB

P1476

Q39888907-A0E73C03-6013-4C6C-A7FB-4814749408D6

P2093

Q39888907-4814532E-87DC-43C8-BC0F-3E0994C059DF

Q39888907-6DB17586-019B-464E-ADA3-F5BDA8E54E2F

Q39888907-B91054DA-48D9-4F78-AD30-85EFB9EB7A80

Q39888907-E110D77E-1A1F-48A0-B049-CF8CFC215426

Q39888907-EEF0B46B-C0A3-4227-B7AF-1F3D445EA92F

P2860

Q39888907-1375AD68-0B5E-473F-BFD8-7C5E91536120

Q39888907-33DF0017-F3B1-4C31-B210-5A69FEEF785B

Q39888907-39F61428-52B7-443B-A3DC-0CCBEC3B205C

Q39888907-503CE241-BC08-430B-8950-08CB3D663526

Q39888907-5857EBA8-59D5-4A95-9639-55408DEB8CE6

Q39888907-5F381E63-AB25-493B-8AFE-B4E5028079AD

Q39888907-6D12083F-DC10-41EE-BB18-895B95035117

Q39888907-84E17829-A442-4AE5-A034-82FFFC31BB66

Q39888907-8A50C218-C95F-49B2-9EC9-C7E73CA1C8FF

Q39888907-984C0B85-B860-4908-81B2-ECA2600C38AA

P304

Q39888907-7B99476A-50BD-4CA9-983D-0EA594DA3471

P31

Q39888907-174F8C03-447E-43C1-A3C5-DEC657A7E808

P356

Q39888907-87CE7E73-CA68-4D2D-A252-03A2591DB358

P407

Q39888907-428F0DD7-66FC-4EB9-9A50-F401992EF143

P433

Q39888907-B5DC7D1C-CAB5-4881-8170-85D414BFCA74

P478

Q39888907-FE120DBC-D0AB-4538-AE0F-9D21E105F205

P577

Q39888907-78FFC091-ED2E-4F66-9ACE-EB2C2EF05C16

P5875

Q39888907-C024129A-9608-4215-A6C5-0764C94229B4

P698

Q39888907-5A664D8C-1A66-4064-9B94-12BA65617A2F

P932

Q39888907-6D456CB5-443B-417F-8021-7E5457F7FFD6

P356

P1433

P1476

Rational approach to implementation of prostate cancer antigen 3 into clinical care.

@en

P2093

Arul M Chinnaiyan

http://www.w3.org/2001/XMLSchema#string

John T Wei

http://www.w3.org/2001/XMLSchema#string

Kirk J Wojno

http://www.w3.org/2001/XMLSchema#string

Rodney L Dunn

http://www.w3.org/2001/XMLSchema#string

Rou Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate

DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Phases of biomarker development for early detection of cancer.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Purification of a human prostate specific antigen.

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

P304

3879-3886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.24447

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26283601

http://www.w3.org/2001/XMLSchema#string

P698

19517474

http://www.w3.org/2001/XMLSchema#string

P932

2746943

http://www.w3.org/2001/XMLSchema#string